Ascletis Pharma reports share capital reduction, increased treasury shares in November

Ascletis Pharma Inc. recorded a decrease of 100,000 in its total number of issued shares to 998,958,530 for November 30, 2025. This reduction was primarily due to share repurchases. The number of issued shares (excluding treasury shares) also declined by 100,000, settling at 991,974,320, while treasury shares increased by 100,000 to 6,984,210.

The company's authorized/registered share capital remained stable at 7,000,000,000 ordinary shares with a par value of $0.0001, totaling $700,000. During the month, 160,000 share options approved on June 6, 2019, were cancelled, reducing outstanding options to 7,243,653.

Ascletis Pharma Inc. also reported outstanding repurchases for cancellation totaling 960,000 shares (HK$9.2396 per share) that had not yet been cancelled as of November 30, 2025. These include 800,000 ordinary shares repurchased in April 2025 and an additional 160,000 ordinary shares repurchased in October 2025.